• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma].重组人内皮抑素治疗晚期肺鳞状细胞癌
Zhongguo Fei Ai Za Zhi. 2016 Oct 20;19(10):670-674. doi: 10.3779/j.issn.1009-3419.2016.10.06.
2
Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.恩度联合培美曲塞/顺铂化疗后序贯恩度联合培美曲塞维持治疗非小细胞肺癌的疗效及安全性：与标准化疗的回顾性比较。
Thorac Cancer. 2018 Nov;9(11):1354-1360. doi: 10.1111/1759-7714.12827. Epub 2018 Aug 27.
3
The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.恩度联合化疗治疗晚期非小细胞肺癌的持续输注评价。
Chemotherapy. 2018;63(4):214-219. doi: 10.1159/000493098. Epub 2018 Oct 22.
4
Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.重组人内皮抑素在晚期非小细胞肺癌放疗期间的疗效与安全性
Future Oncol. 2022 Mar;18(9):1077-1087. doi: 10.2217/fon-2021-1239. Epub 2022 Jan 6.
5
[Clinical Observation of Recombinant Human Vascular Endostatin Durative Transfusion Combined with Window Period Arterial Infusion Chemotherapy in the Treatment of 
Advanced Lung Squamous Carcinoma].重组人血管内皮抑素持续输注联合窗口期动脉灌注化疗治疗晚期肺鳞癌的临床观察
Zhongguo Fei Ai Za Zhi. 2015 Aug;18(8):500-4. doi: 10.3779/j.issn.1009-3419.2015.08.05.
6
Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.重组人血管内皮抑制素联合化疗治疗非驱动基因突变晚期非小细胞肺癌的真实世界结局。
Cancer Med. 2019 Apr;8(4):1434-1441. doi: 10.1002/cam4.2014. Epub 2019 Feb 14.
7
[Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].恩度联合化疗多周期治疗晚期非小细胞肺癌患者的疗效
Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):937-42.
8
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.一项多中心、随机、双盲、安慰剂对照研究，旨在评估紫杉醇-卡铂单独或联合恩度治疗晚期非小细胞肺癌的疗效。
J Thorac Oncol. 2011 Jun;6(6):1104-9. doi: 10.1097/JTO.0b013e3182166b6b.
9
[Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].重组人血管内皮抑素联合多西他赛用于晚期非小细胞肺癌二线治疗或一线治疗不耐受毒性的疗效与安全性
Zhonghua Zhong Liu Za Zhi. 2013 Aug;35(8):618-22.
10
[A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].一项多中心、随机、双盲、安慰剂对照的安全性研究，旨在评估单独使用紫杉醇-卡铂（PC）或联合恩度治疗晚期非小细胞肺癌（NSCLC）的临床疗效和生活质量
Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):854-9.

引用本文的文献

1
Recombinant human endostatin combined with radiotherapy promotes cardiomyocyte apoptosis in rats via TGFβ1/Smads/CTGF signaling pathway.重组人血管内皮抑制素联合放疗通过 TGFβ1/Smads/CTGF 信号通路促进大鼠心肌细胞凋亡。
BMC Cardiovasc Disord. 2022 Mar 12;22(1):97. doi: 10.1186/s12872-022-02499-8.
2
Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: A retrospective observational study.恩度联合吉西他滨/顺铂方案不同给药方式对局部晚期或转移性肺鳞癌的影响：一项回顾性观察研究
Medicine (Baltimore). 2018 Aug;97(32):e11822. doi: 10.1097/MD.0000000000011822.
3
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.恩度联合化疗治疗小儿骨肉瘤肺转移并恶性胸腔积液1例报告
Medicine (Baltimore). 2017 Dec;96(51):e9077. doi: 10.1097/MD.0000000000009077.

本文引用的文献

1
Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer.一项随机、双盲、安慰剂对照的III期试验的长期结果：恩度（重组人血管内皮抑制素）与安慰剂联合长春瑞滨和顺铂治疗晚期非小细胞肺癌的对比研究
Thorac Cancer. 2013 Nov;4(4):440-448. doi: 10.1111/1759-7714.12050.
2
Cancer statistics, 2015.癌症统计数据，2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
3
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.一项雷莫芦单抗联合紫杉醇和卡铂作为 IIIB/IV 期非小细胞肺癌一线治疗的 II 期、开放标签研究。
J Thorac Oncol. 2014 Oct;9(10):1532-9. doi: 10.1097/JTO.0000000000000273.
4
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.雷莫芦单抗联合多西他赛对比安慰剂联合多西他赛二线治疗铂类化疗后进展的 IV 期非小细胞肺癌（REVEL）：一项多中心、双盲、随机 III 期临床试验。
Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.
5
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.IV 期非小细胞肺癌的治疗：肺癌的诊断与管理，第 3 版：美国胸科学会循证临床实践指南。
Chest. 2013 May;143(5 Suppl):e341S-e368S. doi: 10.1378/chest.12-2361.
6
Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence.新型重组人血管内皮抑制素通过肿瘤血管重构增强放射反应：实验与临床证据。
Radiother Oncol. 2013 Jan;106(1):130-7. doi: 10.1016/j.radonc.2012.10.022. Epub 2013 Jan 23.
7
FGFR1 amplification in squamous cell carcinoma of the lung.肺鳞状细胞癌中 FGFR1 扩增。
J Thorac Oncol. 2012 Dec;7(12):1775-1780. doi: 10.1097/JTO.0b013e31826aed28.
8
[A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].一项多中心、随机、双盲、安慰剂对照的安全性研究，旨在评估单独使用紫杉醇-卡铂（PC）或联合恩度治疗晚期非小细胞肺癌（NSCLC）的临床疗效和生活质量
Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):854-9.
9
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.明确生物标志物验证的肺鳞癌中驱动癌基因突变谱：缺乏 EGFR/KRAS 而存在 PIK3CA/AKT1 突变。
Clin Cancer Res. 2012 Feb 15;18(4):1167-76. doi: 10.1158/1078-0432.CCR-11-2109. Epub 2012 Jan 6.
10
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.男性肺腺癌患者肿瘤标本中 EGFR 外显子 19 缺失和 L858R 的发生率。
J Clin Oncol. 2011 May 20;29(15):2066-70. doi: 10.1200/JCO.2010.32.6181. Epub 2011 Apr 11.

重组人内皮抑素治疗晚期肺鳞状细胞癌

[Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma].

作者信息

Xing Puyuan, Hao Xuezhi, Hu Xingsheng, Wang Yan, Li Junling

机构信息

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
Beijing 100021, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2016 Oct 20;19(10):670-674. doi: 10.3779/j.issn.1009-3419.2016.10.06.

DOI:10.3779/j.issn.1009-3419.2016.10.06
PMID:27760596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5973421/
Abstract

BACKGROUND

Squamous cell carcinoma (SCC) is a common pathological type of non-small cell lung cancer, and advanced lung SCC is incurable. Chemotherapy combined with anti-angiogenesis agents can prolong the patients' survival time. The aim of the study was to analyze the efficacy and safety of recombinant human endostatin (Endostar) in treating advanced lung SCC.

METHODS

We retrospectively analyzed the short-term efficacy and toxicity of recombinant human endostatin combined with traditional chemotherapy regimens in treating 15 advanced lung squamous cell carcinoma patients in Department of Medical Oncology retrospectively, Cancer Hospital, Chinese Academy of Medical Sciences from November 2011 to May 2015. Treatment-related survival was also analyzed.

RESULTS

Among the evaluble 14 patients, the best overall response was partial response in 5 patients (35.7%), stable disease in 7 patients (50.0%), and progressive disease in 2 patients (14.3%). The objective response rate (ORR) was 35.7%, and disease control rate (DCR) was 85.7%. The median progression-free survival (PFS) was 9.3 months. The main grade 3 toxicity was neutropenia (2/15, 13.3%) and vomitting (1/15, 6.7%).

CONCLUSIONS

Chemotherapy combined with recombinant human endostatin enabled good objective response in advanced SCC patients and had well security.

摘要

背景

鳞状细胞癌（SCC）是非小细胞肺癌常见的病理类型，晚期肺鳞癌无法治愈。化疗联合抗血管生成药物可延长患者生存时间。本研究旨在分析重组人血管内皮抑素（恩度）治疗晚期肺鳞癌的疗效和安全性。

方法

回顾性分析2011年11月至2015年5月中国医学科学院肿瘤医院肿瘤内科15例晚期肺鳞癌患者采用重组人血管内皮抑素联合传统化疗方案的近期疗效及毒性反应，并分析治疗相关的生存情况。

结果

14例可评价患者中，最佳总体反应为部分缓解5例（35.7%），病情稳定7例（50.0%），疾病进展2例（14.3%）。客观缓解率（ORR）为35.7%，疾病控制率（DCR）为85.7%。中位无进展生存期（PFS）为9.3个月。主要3级毒性反应为中性粒细胞减少（2/15，13.3%）和呕吐（1/15，6.7%）。

结论

化疗联合重组人血管内皮抑素可使晚期肺鳞癌患者获得较好的客观反应，且安全性良好。